

# Paul Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4382368/publications.pdf>

Version: 2024-02-01

9  
papers

111  
citations

1307366

7  
h-index

1474057

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

115  
citing authors

#	ARTICLE	IF	CITATIONS
1	BQ323636.1, a Novel Splice Variant to <i>NCOR2</i> , as a Predictor for Tamoxifen-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3681-3691.	3.2	23
2	Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 869-879.	0.8	21
3	Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study. <i>Blood Advances</i> , 2021, 5, 2829-2838.	2.5	18
4	Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10232.	1.8	17
5	Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting. <i>Hematology</i> , 2020, 25, 247-257.	0.7	13
6	B Cell Subsets and Cellular Signatures and Disease Relapse in Lupus Nephritis. <i>Frontiers in Immunology</i> , 2020, 11, 1732.	2.2	8
7	Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation. <i>Cancer Medicine</i> , 2020, 9, 3371-3382.	1.3	7
8	Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4647.	1.8	3
9	Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5670.	1.8	1